Feature | July 07, 2010| Dave Fornell

Big Strides Made to Expand Interventional Offerings

Three companies made significant purchases and product introductions in May and June in efforts to gain a larger share of the interventional, cath lab device market.

Combining IVUS, Therapeutic Devices

Volcano Corp. told Diagnostic and Invasive Cardiology earlier this year it plans to diversify its business from intravascular imaging systems and fractional flow reserve (FFR) catheters to interventional treatment devices. It received its first therapy device regulatory clearance in Europe for the Vibe RX, a single catheter combining intravascular ultrasound (IVUS) with an angioplasty balloon. The catheter reduces the need for multiple exchanges, helping to speed procedure times and cut costs.

The Vibe RX is the first of what the company hopes will be many image-guided therapy devices. Volcano’s initial focus is on cardiovascular applications, but it will eventually leverage the combo technology for other applications throughout the body.

The company also plans to expand its interventional offerings through partnerships with other device manufacturers. Earlier this year Volcano entered into a Japanese distribution agreement with AngioScore for its AngioSculpt PTCA scoring balloon catheter.

OCT Cleared, Then Purchased

Soon after the U.S. Food and Drug Administration (FDA) cleared LightLab Imaging’s optical coherence tomography (OCT) intravascular imaging system, St. Jude Medical purchased the company. The $90 million purchase will make St. Jude the only company in the United States to offer OCT, which provides image resolution 10 times greater than IVUS. The technology is expected to offer serious competition for IVUS makers Boston Scientific and Volcano.

St. Jude said OCT is expected to bring in an extra $20 million in revenue during the second half of 2010. The company also expects the OCT market to grow at a double-digit, compounded annual rate over the next five years. The IVUS market is estimated to be $500 million for 2010 and is growing 10 to 15 percent annually. St. Jude said the OCT coronary imaging is expected to grow at an even faster rate.

Volcano also developed an OCT system, which gained European clearance in January. The company is now awaiting FDA investigational device exemption (IDE) approval so it can start its U.S. clinical trial. Volcano hopes to release its OCT system in the United States by mid-2011.

Expanding Into the Interventional Market

Covidien Ltd. recently purchased ev3 Inc. for $2.6 billion to expand its percutaneous vascular portfolio. The company said it hopes to become a leading endovascular player in both the peripheral vascular and neurovascular markets.

Ev3 Inc. developed several technologies for the treatment of peripheral vascular and neurovascular diseases. These products include peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, flow diversion, thrombectomy catheters and occlusion balloons.

Last year, Covidien purchased VNUS Medical Technologies and Bacchus Vascular to expand its vascular interventional business. VNUS is a leading provider of medical devices and procedures for the minimally invasive treatment of venous reflux disease. Bacchus Vascular offers the Trellis thrombolysis peripheral infusion system to treat deep vein thrombosis (DVT).

Detailed information on the use of the Trellis device can be found in this issue’s story on clot busting technologies on page 6.

Related Content

IVPA, intravascular photoacoustic imaging, fatty arteries, Purdue, Shanghai

IVPA/IVUS imaging of a perfused fresh human right coronary artery dissected from an explanted heart. (A) IVPA image. (B) IVUS image. (C) Merged IVPA/IVUS image. The 1 mm scale bar applies to all panels.

News | Intravascular Imaging| May 25, 2016
A new imaging system known as intravascular photoacoustic (IVPA) imaging that produces three-dimensional images of the...
cardiac magnetic resonance, CMR, breathing, high frequency percussive ventilation, EuroCMR 2016
News | Magnetic Resonance Imaging (MRI)| May 24, 2016
A new technique for cardiac magnetic resonance (CMR) imaging improves accuracy by removing patients' need to breathe,...
HeartFlow, FFR-CT, ruptured coronary plaques, EMERALD study, EuroPCR 2016
News | CT Angiography (CTA)| May 23, 2016
First-in-human data presented at EuroPCR 2016 demonstrate that hemodynamic data from HeartFlow Inc. may help predict...
PCI, OFDI, OCT, optical coherence tomography, optimal frequency domain imaging, EuroPCR 2016 study
News | Intravascular Imaging| May 20, 2016
Using optimal frequency domain imaging (OFDI) to guide percutaneous coronary intervention (PCI) with second-generation...
Technology | Cardiac Imaging| May 18, 2016
May 18, 2016 — The Intersocietal Accreditation Commission (IAC) recently announced its launch of the IAC QI Self-Asse
Sponsored Content | Videos | HIMSS| May 13, 2016
ITN/DAIC Editor Dave Fornell takes a tour of some of the most innovative new trends and health information t
vulnerable plaques, OCT, IVUS, catheter, combination, NIBIB study

The dual catheter OCT-IVUS imaging device can be inserted into an artery to simultaneously capture an infrared image of the arterial wall (OCT, at left) and an ultrasound image (IVUS, right) that doctors use to determine the potential that a plaque is susceptible to rupture that could cause a heart attack or stroke.

News | Intravascular Imaging| May 12, 2016
May 12, 2016 — Collaboration between two National Institute of Biomedical Imaging and Bioengineering (NIBIB)-funded l
Radiation dose management, radiation dose monitoring, X-ray dose

Analytics from Sectra’s radiation dose monitoring software showing procedures where dose levels were higher than normal for various X-ray modalities. 

Feature | Radiation Dose Management| May 12, 2016 | Lori Webb, R.T. (R) and Tom Watson, RCVT
Healthcare organizations, clinicians and medical equipment manufacturers have long focused on the management and redu
GE Ultrasound, GE echo, strain, cardio-oncology

GE Healthcare's cardiac ultrasound cardiac strain assessment software helps quanitify left ventricular wall motion to determine if there is damage to cardiac function due to cancer therapy.

Feature | Cardio-oncology| May 11, 2016 | Dave Fornell
Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat...
Overlay Init